Top Boston, MA Biotech Companies (271)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products. Help us bring modern software to modern science. We’re on Team Science We believe in the promise of science and the teamwork required to fulfill that promise. Whether your background is in science, engineering, business, or another field, you’re on Team Science if you believe in the power of science to solve the world’s most pressing problems.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and technology, and we’re proud of our employees and their commitment to turning groundbreaking ideas into life-changing impacts. Since our founding in Japan, integrity and putting patients first have been at the heart of our identity, and we will emerge ready for our future as one of the most trusted and science-driven digital biopharmaceutical companies. Join a team where your innovation impacts lives. Together, we’ll realize improved outcomes by improving data quality, enhancing launch execution and improving the patient journey. You’ll play a critical role in accelerating data collection and increasing accuracy across all parts of the business. Patients across the globe will benefit from access to treatments afforded by greater opportunities and efficiency in our research and development.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. Click Therapeutics continuously expands and refines its platform with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. The digital therapeutics under development on Click’s platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. Consistently named a best place to work, Click fosters an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in a common mission to provide patients everywhere access to safe and effective prescription digital therapeutics. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to [email protected]. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and change how brain disorders are thought about and treated. Our mission is to pioneer solutions with the potential to deliver life-changing brain health medicines, so every person can thrive. Welcome To The Workplace With A Difference At Sage, we believe that life is more than just a destination. We’re concerned with the journey, and we care deeply about everyone contributing to and benefiting from our own company journey. This means helping people discover the right path for them and carefully guiding colleagues along the way. Read our Community Guidelines: http://bit.ly/2tFyAoj
Gatehouse Bio is developing therapeutics that correct the effects of disease-driving mutations in small RNA genes. We believe there is an RNA code that can treat every disease. Our mission is to find that code and use it to develop effective therapeutics. Our platform is the first to use AI to discover small RNA mutations and design oligonucleotides that crack a disease’s code. Our pipeline and partnerships are focused on developing drugs for therapeutic areas with known heterogeneity such as fibrosis, inflammation and neurodegeneration. With every single code we break, we unlock the potential to improve the lives of many.
Committed to the long-term success and impact of its portfolio companies, CSB offers deep domain expertise, connections to a broad network of industry and scientific leaders, and access to unique sources of health data.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
StackWave provides software solutions to help rapidly growing life science organizations scale research and operations in order to get to the clinic as quickly as possible. Our client-partners range from early-stage biotechs to public companies and large research institutions.
Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA. We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery. Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery. We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients. Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.
Montai Health is focused on unlocking the power of nature to create Anthromolecule™ medicines that treat and preempt a broad range of human diseases, with an initial focus on inflammatory and autoimmune diseases. Montai's CONECTA™ platform comprehensively maps Anthromolecule bioactivity across pathways that drive disease. The CONECTA platform leverages rapid and ever-growing advancements in the digitization of natural chemistry and human biology coupled with powerful computational tools for linking chemical structure and bioactivity. This confluence of biotechnologies enables Montai to build a powerful, one-of-a-kind discovery platform focused on creating safe, effective, and more human-centric medicines than ever before. Montai Health was founded in Flagship Labs in 2019. For more information, please visit www.montai.com.
Pioneering generative biology to create breakthrough therapeutics.
Our mission is to cure disease by writing the code of life
Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.
Conagen is an accomplished biotechnology company located in the greater Boston biotech corridor. We innovate and develop synthetic biology solutions for supporting global partners across a spectrum of current and developing markets. From our proprietary strain development to fermentation and process scale-up, Conagen impacts partners’ abilities to sell and market products in the food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. Our bio-manufacturing capabilities, coupled with extensive platforms of enzymes and microorganisms, gives us the edge in commercial biotechnology. Nature is our inspiration for designing metabolic pathways, improving production organisms, and optimizing production processes. Our discovery and development methods foster sustainability and improve efficiency—from lab to world scale. Plant biology ignited the spark for the creation of Conagen. Today, our bioengineering teams are experts in enzymatic bioconversion and fermentation technology. Nature is our guide for innovating ways to produce natural products and materials. This approach gets us to market faster with better products made competitively and sustainably. Simply, our distinction is creating molecules that are identical to what nature produces. Many of the innovative natural products we make at Conagen are truly proprietary. They are the only ones on the market that are made by natural fermentation which means they are produced biologically and sustainably unlike most chemically synthesized products. As a vertically integrated biotech company, we engage in research and development as well as world-scale production. The advantage at Conagen is our ability to direct the manufacturing of our products. We can rapidly scale our strains to produce what our partners need while maintaining the highest level of quality control throughout the entire process. Scaling up from micrograms to metric tons is our expertise.
Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential. Applying our nimble, proven approach to accelerate clinical development, we aim to translate our molecules into first-in-class or best-in-class medicines. The patient, clinician and academic communities are our collaborators in every step of development from bench to bedside. Our accomplished team holds a track record of success in making medicines for rare diseases and neurology. Our goal is bold for the communities we serve. For more information, please visit www.ovidrx.com. Review our community guidelines: http://www.ovidrx.com/community-guidelines/
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.
GreenLight Biosciences is a mission-driven public-benefit corporation using the power of RNA to tackle some of humanity's greatest challenges, including pandemics, rare diseases, biodiversity and climate change.
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com,
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts with cutting through complexity and focusing on the human side of healthcare. By continuously advancing and integrating our solutions, we enable clinicians to be vitally connected to their patients by delivering timely data and actionable insights. That means more accurate diagnoses, earlier intervention and faster recovery times. Our innovations put more heart in healthcare. Through more intelligent—and more connected—solutions, we help simplify routine workflows and communication, enabling care teams to focus on their passion—helping patients get better sooner. And we continuously raise the bar on quality and safety, building upon our legacy of trust with providers around the world. As healthcare continues to evolve, we’re here to support the people at the heart of it. Hillrom. Advancing Connected Care™.
Work Your Passion. Live Your Purpose.
